Anocca signs licensing deal for EmendoBio’s gene-editing tech

2024-03-15

基因疗法引进/卖出细胞疗法

Anocca signs licensing deal for EmendoBio’s gene-editing tech

Preview

来源: Pharmaceutical Technology

EmendoBio’s technology will aid Anocca in delivering tailored therapies to patients more rapidly. Credit: Natali _ Mis / Shutterstock.com.

Preview

来源: Pharmaceutical Technology

Swedish biotech company Anocca has entered a non-exclusive licensing agreement with EmendoBio to use the latter’s OMNI-A4 nuclease, a gene editing technology [that cleaves chains of nucleotides in nucleic acids into smaller units].

This strategic move is set to expedite developing and manufacturing Anocca’s pipeline of T cell receptor-engineered T cell (TCR-T) therapies, targeting difficult-to-treat solid cancers.

The latest development comes after Anocca received good manufacturing practice compliance certification and a manufacturing licence from regulators in Sweden for its cell therapy production facility.

Anocca CEO and co-founder Reagan Jarvis stated: “Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products.

“This next-generation gene editing system provides the precision and efficiency needed to scale out production of our growing libraries of TCR-T products in a high-precision manufacturing process.

See Also:

Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech

Preview

来源: Pharmaceutical Technology

Almirall to license Eloxx’s ZKN-013 for rare skin conditions

Preview

来源: Pharmaceutical Technology

“We are excited to work with EmendoBio to develop gene-edited TCR-T cell therapies as we prepare for our first clinical programme targeting the KRAS driver mutation in a hard-to-treat solid cancer.”

EmendoBio’s technology is expected to significantly enhance Anocca’s manufacturing expertise.

It will also aid the company in delivering tailored therapies to patients more rapidly, focusing on the genetic causes of hard-to-treat cancer types.

The licensed gene editing technology is part of EmendoBio’s nuclease suite designed for high activity and specificity within cell therapy applications.

EmendoBio director Dr Ei Yamada stated: “This non-exclusive licensing agreement marks a significant milestone in the field of T cell therapy.

“Together with Anocca, we are embracing the shared vision of harnessing the potential of gene editing and cellular therapies to make a profound impact on patient outcomes. Our combined expertise will unlock novel avenues for therapeutic development and push the boundaries of what’s possible in advanced medicine.”

In May 2023, Anocca secured Skr400m ($38.9m) in an equity financing round to develop next-generation cell therapies for cancer on an industrial scale.

AMF and Mellby Gård led the funding round.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline

The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.

By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构